NMDA receptor binding in focal epilepsies

C J McGinnity,1,2,3 M J Koepp,4,5 A Hammers,1,2,3,4,5,6 D A Riaño Barros,1,2 R M Pressler,7 S Luthra,8 P A Jones,8 W Trigg,8 C Micallef,9 M R Symms,4,5 D J Brooks,1,10 J S Duncan4,5

ABSTRACT

Objective To demonstrate altered \(N\)-methyl-\(d\)-aspartate (NMDA) receptor availability in patients with focal epilepsies using positron emission tomography (PET) and \(^{18}\)F-GE-179, a ligand that selectively binds to the open NMDA receptor ion channel, which is thought to be overactive in epilepsy.

Methods Eleven patients (median age 33 years, 6 males) with known frequent interictal epileptiform discharges had an \(^{18}\)F-GE-179 PET scan, in a cross-sectional study. MRI showed a focal lesion but discordant EEG changes in two, was non-localising with multifocal EEG abnormalities in two, and was normal in the remaining seven patients who all had multifocal EEG changes. Individual patient \(^{18}\)F-GE-179 volume-of-distribution (VT) images were compared between individual patients and a group of 10 healthy controls (47 years, 7 males) using Statistical Parametric Mapping.

Results Individual analyses revealed a single cluster of focal VT increase in four patients; one with a single and one with multifocal MRI lesions, and two with normal MRIs. Post hoc analysis revealed that, relative to controls, patients not taking antidepressants had globally increased \(^{18}\)F-GE-179 VT (+28%; \(p<0.002\)), and the three patients taking an antidepressant drug had globally reduced \(^{18}\)F-GE-179 VT (−29%; \(p<0.002\)). There were no focal abnormalities common to the epilepsy group.

Conclusions In patients with focal epilepsies, we detected primarily global increases of \(^{18}\)F-GE-179 VT consistent with increased NMDA channel activation, but reduced availability in those taking antidepressant drugs, consistent with a possible mode of action of this class of drugs. \(^{18}\)F-GE-179 PET showed focal accentuations of NMDA binding in 4 out of 11 patients, with difficult to localise and treat focal epilepsy.

INTRODUCTION

\(N\)-methyl-\(d\)-aspartate (NMDA) receptors are ligand-gated and voltage-gated ion channels that mediate fast excitatory neurotransmission in the central nervous system (CNS).1,2 NMDA receptor-mediated neurotransmission is necessary for cognition, memory and neuronal survival, but excessive NMDA receptor activation mediates excitotoxic neuronal injury following acute cerebral insults,3 is associated with cell death4 and is thought to contribute to disorders of neuronal hyperexcitability, such as epilepsy and neuropathic pain, and chronic neurodegenerative diseases,5 depression6,7 and schizophrenia.8 In chemical models, administration of agonists of either the NMDA or \(\alpha\)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors induces convulsions in vivo either by directly mediating an epileptic depolarisation through the NMDA calcium channels or by indirectly activating NMDA channels subsequent to AMPA/kainate receptor activation9–11 (for review: ref. 12). Blockade of NMDA receptors is neuroprotective,13 prevents paroxysmal depolarisation shifts, which are the intracellular correlate of interictal epileptiform discharges (IEDs),14–17 and blocks the development of kindling.18–20 Several21 22 but not all kindling model studies have shown the presence of increased NMDA receptor availability in the hippocampus and cerebral cortex of epileptic animals. Autoradiography of human epileptogenic temporal lobe tissue has revealed increased NMDA receptor availability in the parahippocampal gyrus, in contrast to decreased availability in the hippocampus, particularly in sclerotic regions.23 24 In vitro studies in tissue dissected from patients with epilepsy have associated NMDA receptor-mediated neurotransmission with epileptic activity.25–30 Receptor activation, however, can only be shown in vivo. Human microdialysis studies have revealed marked elevations in extracellular glutamate concentration preceding and during seizures,31–37 which would be expected to result in increased NMDA receptor activation. Hence, there is interest in the development of radioligands that allow assessment of NMDA receptor function in humans in vivo.

We have previously observed good brain penetration, moderately heterogeneous distribution in grey matter and suitably rapid washout of the novel NMDA positron emission tomography (PET) tracer \(^{18}\)F-GE-179 in healthy controls.38 This ligand binds at the phencyclidine (PCP) recognition site39 within the NMDA ion channel pore, and hence requires receptor activation for access. This ‘pore-blocker’ ligand could potentially allow use-dependent imaging of the NMDA receptor in the active/open state using PET. We report the first use of \(^{18}\)F-GE-179 PET in focal epilepsies of different focal and multifocal onset. The objective of this proof-of-principle study was to demonstrate in vivo a hypothesised increased NMDA receptor activation in patients with drug-resistant epilepsy.

METHODS

The study was approved by the Research Ethics Committees of the Royal Marsden Hospital, Imperial College Healthcare NHS Trust and University College London Hospitals NHS
Foundation Trust. Permission to administer [18F]GE-179 was obtained from the Administration of Radioactive Substances Advisory Committee (ARSAC), UK. All participants provided written, informed consent.

Epilepsy and control populations

This was a proof-of-principle, cross-sectional pilot study with targets of 12 participants per group. Eleven patients with refractory focal epilepsies (median age 33 years; range 20–50 years; 6 males) were recruited from the outpatient clinics at the National Hospital for Neurology and Neurosurgery. Demographics and clinical details are listed in table 1. Their diagnoses were based on history, seizure semiology, prolonged and repeated interictal and ictal EEG recordings (where available), and MRI data. Patients were chosen who had frequent interictal spikes on previous EEG recordings, which we hypothesised would maximise our chances to detect increased binding to open NMDA receptors. None of the patients were taking an antiepileptic drug (AED) known to act at the NMDA receptor. Exclusion criteria included inability to provide informed consent, claustrophobia, standard MR contraindications, a positive urinary pregnancy test on the day of the PET scan and history of drug abuse. Patient 4, whose seizures consisted of a sustained fluctuation of perception of brightness with pupillary hippus, has been presented in a detailed case report.40

The control group, 9 of whom have been described previously,38 comprised 10 healthy volunteers without history of neurological or psychiatric illness (median age 46 years; range 25–62 years; 7 males). Additional exclusion criteria were as described for the patients above. A further three seemingly healthy individuals were subsequently excluded; one due to excessive movement throughout the PET scan acquisition, one whose MRI revealed evidence of a cerebral infarct; and one who was discovered to have a history of benzodiazepine abuse. The original control group data were used, rather than repeat images; the patient data were acquired at approximately the same time as those of the control group (i.e. within 12 months) using the same imaging protocol.

Median age and body mass index (BMI) were compared between patients and control groups by Mann-Whitney U statistic in SPSS. Gender balance was compared between groups with the (Pearson) \( \chi^2 \) test.

MRI data acquisition

Three-dimensional volumetric T1-weighted coronal MRI sequences were acquired at Epilepsy Society (Chalfont St. Peter, UK), as previously described.38 MRIs were reviewed by an experienced neuroradiologist (CM). MRIs were not available for one control participant, in whom 3.0 T MRI was contraindicated.

EEG

All patients had an EEG during the PET scan using a TRACKit 18/8 (Lifelines Limited, Hants, UK) ambulatory EEG recorder and an EC1 E1 Cap (Electro-Cap International, Eaton, Ohio, USA) with 19 electrodes placed according to the International 10–20 system. An additional reference electrode (Fpz) was sited just anterior to Fz. The O1 and O2 electrodes were removed from the cap prior to scanning for several patients in order to minimise discomfort. The participants were closely observed for evidence of seizures throughout the scan. EEGs were reviewed by an experienced clinical neurophysiologist (RMP). The number of IEDs during the first 30 min of scan acquisition was quantified and correlated with [18F]GE-179 global volume-of-distribution (\( V_T \)) using Spearman’s \( r \) correlation coefficient.

PET image acquisition and data analysis

PET image acquisition has been described previously.38 Briefly, images were acquired using a Siemens/CTI ECAT EXACT 3D 962 HR+PET camera (Siemens, Erlangen, Germany) at Hammersmith Imanet Limited. Each participant had a 90 min dynamic emission scan with a smooth bolus intravenous injection of median 187 MBq (range 173–192 MBq) [18F]GE-179 administered 30 seconds after starting image acquisition. For calculation of continuous decay-corrected and metabolite-corrected parent plasma input functions, discrete arterial blood samples were taken throughout the scan, with continuous arterial blood sampling for the first 15 minutes.

The area under the metabolite model curves (AUCmetabs) was used as a measure of the rate of metabolism for each individual. The AUCmetabs over \( t=0–30 \) minutes and \( t=0–90.5 \) minutes was compared between groups by multivariate general linear model (GLM), with gender as a fixed factor, and age and BMI as covariates. The residual sum of squares (RSSmetabs) for the metabolite model curve was compared between groups by univariate GLM. The threshold for statistical significance was \( p=0.05 \).

The \( V_T \) of [18F]GE-179 was computed at the voxel level for each participant by exponential spectral analysis, as described previously.38 Each participant’s \( V_T \) image was spatially normalised using a scanner-specific template. To enable group-wise comparisons, images acquired from patients with an epileptogenic zone in the right hemisphere (3 patients) were left-right flipped prior to normalisation; three control participants’ images were also left-right flipped prior to group-wise comparison (controls 1, 4 and 6, selected at random). For individual (1 patient vs 10 controls) comparisons, the native (unflipped) patient and control images were used.

The primary outcome measure, global \( V_B \), was computed as an overall mean over the entire matrix, thresholded at 1/8 of that value to create a brain mask, and averaged again within this mask. The global \( V_T \) values were compared between groups using a univariate GLM, with gender as a fixed factor, and age and BMI as covariates.

In order to identify changes in the regional distribution of activated NMDA receptors, group-wise SPM8 analyses based on the smoothed (12 mm Full Width at Half Maximum (FWHM) isotropic Gaussian kernel), transformed parametric \( V_T \) images, were performed, comparing patients with focal epilepsy against the controls. The images were compared on a voxel-by-voxel basis using a two-sample t test, assuming unequal variances, with global \( V_T \) taken into account via an analysis of covariance (ANCOVA) by group. The images were grey and white matter (explicit) masked, with relative threshold masking at 0.4. We report differences in [18F]GE-179 \( V_T \) at \( p<0.001 \) (uncorrected), clusters at \( p<0.05 \) (uncorrected) and an extent threshold of 15 voxels.

In order to identify participant-specific changes in the regional distribution of activated NMDA receptors, individual SPM8 analyses based on the smoothed transformed parametric \( V_T \) images were also performed for each of the patients with frequent IEDs against the 10 controls. Equal variances were assumed and global \( V_T \) taken into account via an ANCOVA by group. The unflipped \( V_T \) image for each control participant was compared with those of the nine other controls in an identical fashion.
Table 1  Patients with focal epilepsy and frequent IED—clinical details

<table>
<thead>
<tr>
<th>ID</th>
<th>Age/sex/handedness</th>
<th>Probable localisation MR/EEG/MEG</th>
<th>Onset/ duration (years)</th>
<th>Postictal interval</th>
<th>Treatment</th>
<th>Seizures</th>
<th>EEG</th>
<th>MEG</th>
<th>MRI</th>
<th>Approximately N of observed IEDs (t=0–30 min)</th>
<th>[18F]FDG-PET</th>
<th>Global [18F]GE-179 Vf, increases</th>
<th>[18F]GE-179 Vf, decreases</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>41/F/M/R</td>
<td>L frontal</td>
<td>14.5/26.5</td>
<td>6.0 h</td>
<td>CBZ, LEV, LTG, ZNS</td>
<td>SPS, CPS, SGS</td>
<td>L frontotemporal</td>
<td>NA</td>
<td>R IFG lesion</td>
<td>L temporal</td>
<td>6.16</td>
<td>62</td>
<td>L frontal</td>
</tr>
<tr>
<td>2</td>
<td>22/M/R</td>
<td>L temporal</td>
<td>4/18</td>
<td>7.5 h</td>
<td>CBZ, LEV, LAC</td>
<td>CPS, SGS</td>
<td>L frontotemporal and R temporal</td>
<td>NA</td>
<td>L HS</td>
<td>L hemisphere</td>
<td>7.20</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>38/M/L</td>
<td>Multifocal MRI, EEG/MEG</td>
<td>2.5/36.5</td>
<td>45 min</td>
<td>CBZ, CLB, PHF, TPM, oxofenadine</td>
<td>SPS, CPS, SGS</td>
<td>R frontotemporal</td>
<td>R frontal, L and R temporal</td>
<td>Bilateral tubers: F, P, L-O, periventricular calc</td>
<td>Bilateral tubers: L and R frontal, L temporal, R parieto-occipital, L occipital</td>
<td>4.53</td>
<td>EEG data corrupted</td>
<td>Brainstem; L temporal; R temporal</td>
</tr>
<tr>
<td>4</td>
<td>28/F/R</td>
<td>Multifocal MRI, EEG/MEG</td>
<td>10/18</td>
<td>20.5 h</td>
<td>LEV, sertraline, amlopidine</td>
<td>SPS (pupillary hippus)</td>
<td>R temporoparietal</td>
<td>R parieto-occipital &gt;R temporal &gt;L occipital</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>50/F/R</td>
<td>MRI negative Multifocal EEG/MEG</td>
<td>11/39</td>
<td>39 days</td>
<td>LEV, PH, loperamide</td>
<td>CPS SGS</td>
<td>L=R temporal</td>
<td>L and R temporal</td>
<td>Neg</td>
<td>L temporal</td>
<td>5.32</td>
<td>26</td>
<td>R frontal</td>
</tr>
<tr>
<td>6</td>
<td>33/M/L</td>
<td>MRI negative Unifocal EEG/MEG</td>
<td>19/14</td>
<td>NA</td>
<td>CLN, RUF, fluoxetine</td>
<td>CPS</td>
<td>L temporal</td>
<td>L frontotemporal</td>
<td>Neg</td>
<td>Neg</td>
<td>3.90</td>
<td>168</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>23/M/L</td>
<td>MRI negative Unifocal EEG</td>
<td>16/7</td>
<td>3 days</td>
<td>CBZ, VAL</td>
<td>SPS, SGS</td>
<td>R frontal</td>
<td>NA</td>
<td>Neg</td>
<td>7.72</td>
<td>86</td>
<td>L frontal; R frontal</td>
<td>L temporal; R frontal</td>
</tr>
<tr>
<td>8</td>
<td>40/F/L</td>
<td>MRI negative PET/MEG L Frontal</td>
<td>12.5/28</td>
<td>11 days</td>
<td>CLB, LAC, OXC</td>
<td>SGS</td>
<td>L=R frontal</td>
<td>L F</td>
<td>Neg</td>
<td>8.40</td>
<td>42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>24/M/R</td>
<td>MRI negative Multifocal EEG/MEG</td>
<td>7/17</td>
<td>6.5 h</td>
<td>LAC, LEV, LTG, OXC, CLB</td>
<td>CPS, SGS</td>
<td>R frontocentral</td>
<td>L frontal &gt;L insula. &gt;L frontotemporal</td>
<td>Neg</td>
<td>Neg</td>
<td>8.44</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>50/F/R</td>
<td>MRI negative Multifocal EEG/MEG</td>
<td>13/37</td>
<td>10+ years</td>
<td>LEV, LAC, LTG</td>
<td>CPS</td>
<td>L=R temporal</td>
<td>L and R T</td>
<td>Neg</td>
<td>NA</td>
<td>8.17</td>
<td>Cont epileptiform activity*</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>20/F/R</td>
<td>MRI negative Multifocal EEG</td>
<td>14/6</td>
<td>39.5 h</td>
<td>CLB, OXC,</td>
<td>CPS, SGS</td>
<td>R=L temporal</td>
<td>NA</td>
<td>Neg</td>
<td>8.88</td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Antidepressant drugs (patients 4–6) are displayed in bold font.

*EEG revealed continuous ongoing focal epileptiform activity in patient 10, who had not shown clinically evident seizure activity within the preceding 10 years. Underline indicates concordance between the cluster of increase and the location of the presumed epileptogenic zone, where known.

Calc, calcification; CBZ, carbamazepine; CLB, clonazepam; CLN, clonazepam; CPS, complex partial seizures; EEG, electroencephalography; F, frontal lobe; F/M, female/male; [18F]FDG-PET, [18F]fluorodeoxyglucose positron emission tomography; HS, hippocampal sclerosis; ID, identifying number; IED, interictal epileptiform discharges; IFG, inferior frontal gyrus; L/R, left/right; LAC, lacosamide; LEV, levetiracetam; LTG, lamotrigine; MEG, magnetoencephalography; MRI, magnetic resonance imaging; NA, not available; Neg, negative, that is, no significant findings; O, occipital; OXC, oxcarbazepine; P, parietal lobe; PHF, phenytoin; RUF, rufinamide; SGS, secondary generalised seizures; SPS, simple partial seizures; TPM, topiramate; VAL, valproate; Vf, volume-of-distribution; ZNS, zonisamide.
RESULTS
There was no difference between patient and control group in terms of age (p=1.00), BMI (p=1.00) or gender mix (p=0.47).

There were no significant differences in the AUC\textsubscript{metabs} or the RSS\textsubscript{metabs} between the groups (p=0.19 and p=0.47, respectively). Age, BMI and gender also did not significantly influence the AUC\textsubscript{metabs} (all p>0.09).

Global changes in VT
Global VT was higher in the focal epilepsy group (median 7.51, range 3.77–8.66) than in controls (median 6.21, range 5.37–7.56), although this did not reach statistical significance (p=0.40). There were two distinct subgroups of patients with higher (n=8) and lower (n=3) than normal global VT. To explore this distribution in patients further, post hoc analysis revealed large and significant differences in global VT between patients with focal epilepsy who were not taking antidepressant drugs (median 7.97, range 6.04–8.66; +28% relative to controls), and those who were taking antidepressant drugs (median 4.40, range 3.77–5.15; −29% relative to controls), and controls (6.21, range 5.37–7.56; all p<0.002; figure 1).

There were no differences (in gender, age, AUC\textsubscript{metabs}, RSS\textsubscript{metabs}, BMI, number of IEDs in the first 30 min postinjection) to explain the occurrence of high-VT and low-VT patients other than their use of antidepressants.

Frequent IEDs were noted in the EEG of eight patients throughout the first 30 min of scan acquisition. Global VT did not correlate with the frequency of IEDs measured in the first 30 min after radiotracer injection.

In the following analyses, in order to detect focal increases in activated NMDA receptors over and above global increases, the contribution of global VT to variance was removed by an ANCOVA by group.

Focal changes—group comparisons
There were no common areas of relative focal decrease or focal accentuations of the globally increased \(^{18}\text{F}\)GE-179 \textit{VT} in the patient group compared with controls.

Relative decreases in \textit{VT}—individual comparisons
A focal decrease in \(^{18}\text{F}\)GE-179 \textit{VT} was seen in two healthy control participants (control 3 mid-parietal; control 4 frontal pole). A relative focal decrease in \(^{18}\text{F}\)GE-179 \textit{VT} was seen in two patients (table 2). None of these changes reached significance after correction for multiple comparisons. In one patient (patient 10), the area of relatively decreased \textit{VT} was concordant with one of the multiple tubers seen on MRI.

Relative increases in \textit{VT}—individual comparisons
Focal increases in \(^{18}\text{F}\)GE-179 \textit{VT} were seen in one control participant (control 4), maximal in the left parieto-occipital region. A focal increase above global baseline increase in \(^{18}\text{F}\)GE-179 \textit{VT} was seen in four patients (table 3 and figure 2). Where known, the largest cluster was localised to the lobe of the presumed epileptogenic zone in one, as was the second largest cluster of a further two patients.

DISCUSSION
Using \(^{18}\text{F}\)GE-179 PET, we identified global increases in NMDA receptor ion channel availability for patients with focal epilepsies who were not taking antidepressants, whereas tracer binding was globally decreased in those patients with epilepsy who were also taking antidepressant drugs. Increases in \(^{18}\text{F}\)GE-179 \textit{VT} are consistent with an increase in activated/open NMDA receptors in actively discharging cortex as shown in preclinical work.\textsuperscript{21,22} We suggest that increased NMDA activation in patients with chronic focal epilepsy extends beyond the presumed epileptogenic zone and is a global phenomenon, as reflected in the increased global \textit{VT}.

Our group analyses did not identify any focal redistribution of activated NMDA receptor availability in this group of heterogeneous patients with focal epilepsies arising from different cortical locations; this is perhaps not surprising given the heterogeneity and small sample size. For this pilot study, patients were selected based on the frequency of IEDs on previous EEGs, to maximise our chances of detecting increases in NMDA binding. Concordance of \(^{18}\text{F}\)GE-179 foci with EEG, structural and functional imaging in individual patients is difficult to assess.
given that some of our cohort had normal or EEG-discordant MRI and poorly defined epileptogenic zones: the epileptogenic zone could not be localised using high-resolution MRI, ictal EEG recordings, magnetoencephalography and fluorodeoxyglucose PET (FDG-PET) in four patients, and could only be lateralised to one lobe in four of the remaining seven patients. In contrast, our individual [18F]GE-179 PET analysis identified focal clusters of increased NMDA receptor activation in four patients with focal epilepsy, and these were concordant with the location of the presumed epileptogenic zone in two of those three patients, in whom this could be lateralised to one lobe. Patient 1 was one of the best-localised cases in our cohort, having concordant scalp EEG, [18F]FDG-PET and ictal single-photon emission CT findings. An intracranial EEG recording over the left temporal lobe revealed a diffusely ictal onset, consistent with spread from a nearby lobe. Consistent with these data, a large cluster of increased VT was observed in the left frontal lobe for this participant.

Interestingly, a focal increase in [18F]GE-179 VT was seen in the brainstem of the patient with ictal pupillary hippus in addition to left and right temporal lobe increases (patient 4). The patient is now seizure-free after resection of the tuber in the right parieto-occipital region. Our finding suggests the unusual finding of [18F]GE-179 PET might find clinical application in the presurgical localisation of epileptogenic foci in patients with refractory focal epilepsy with non-contributory MRI.

Intercal regional cerebral blood flow (rCBF) studies usually show reduced perfusion in focal epilepsy, and significant increases in rCBF scans were only seen with prolonged discharges of 8–105 seconds after electrostimulation. Our findings are unlikely to reflect changes in cerebral blood flow (i.e., altered [18F]GE-179 availability) as decreased perfusion in the epileptogenic zone would likely result in decreased [18F]GE-179 availability and thus VT. While NMDA receptor ion channel opening and the excitatory postsynaptic current are extremely rapid events, grey matter uptake and the metabolism of [18F]GE-179 occurs over minutes. Hence, we interpret the VT data as indicative of the integrated extent of NMDA receptor activation during the tracer uptake phase (first 30 min) of the scan.

The lack of focal increases in VT for 7 of the 11 patients with focal epilepsy did not appear to relate to the frequency of scalp-detected IEDs. Global [18F]GE-179 VT was not significantly correlated with the number of IEDs in the first 30 min following injection. The true extent of epileptic activity will not be detectable on scalp EEG, which may explain the lack of correlation between focal spike activity and global [18F]GE-179 uptake. Moreover, it would be oversimplistic to assume a linear relationship between global [18F]GE-179 VT and IED frequency. We expect that NMDA receptors involved in generation of the IED would rapidly internalise or desensitise following their activation. Individual short IEDs would be very difficult to visualise over a 90 min PET scan with [18F]GE-179. We assume any observed increase of [18F]GE-179 binding is related to underlying generalised baseline overactivity, rather than to transient NMDA channel opening over a few milliseconds.

In the only other in vivo PET study of NMDA ion channel activity in epilepsy, Kumlien did not detect focal increases in receptor availability using (S)-[N-methyl-11C]ketamine.

### Table 2: Focal decreases in [18F]GE-179 VT—individual patients versus 10 controls

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Probable localisation (EEG)</th>
<th>MRI</th>
<th>[18F]GE-179 VT decreases</th>
<th>Cluster size (mm³/voxels)</th>
<th>Peak voxel coordinates (x, y, z; mm)</th>
<th>Zmax</th>
<th>Cluster level p (uncorrected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Multifocal</td>
<td>Multiple tubers</td>
<td>R parietal</td>
<td>4864/608</td>
<td>62–32 38</td>
<td>3.62</td>
<td>0.002</td>
</tr>
<tr>
<td>7</td>
<td>R frontal</td>
<td>Negative</td>
<td>L temporal</td>
<td>3968/496</td>
<td>–58–20–22</td>
<td>4.32</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>R frontal</td>
<td>1704/213</td>
<td>10 20–20</td>
<td>3.89</td>
<td>0.040</td>
</tr>
</tbody>
</table>

The cluster(s) reaching significance at p<0.05 uncorrected are listed. The contribution of global VT to variance was removed by an ANCOVA by group. ANCOVA, analysis of covariance; EEG, electroencephalography; ID, identifying number; L/R, left/right; mm, millimeters; MRI, magnetic resonance imaging; VT, volume-of-distribution.

### Table 3: Focal increases in [18F]GE-179 VT—individual patients versus 10 controls

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Probable localisation (EEG)</th>
<th>MRI</th>
<th>[18F]GE-179 VT increases</th>
<th>Cluster size (mm³/voxels)</th>
<th>Peak voxel coordinates (x, y, z; mm)</th>
<th>Zmax</th>
<th>Cluster level p (uncorrected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>L frontotemporal</td>
<td>R IFG lesion</td>
<td>L frontal</td>
<td>7000/875</td>
<td>–322 234</td>
<td>4.46</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>4</td>
<td>Multifocal</td>
<td>Multiple tubers</td>
<td>Brainstem</td>
<td>5152/644</td>
<td>06–28–38</td>
<td>4.58</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>L temporal</td>
<td>3264/408</td>
<td>–32 04–36</td>
<td>4.09</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>R temporal</td>
<td>1720/215</td>
<td>18 04–30</td>
<td>3.97</td>
<td>0.039</td>
</tr>
<tr>
<td>5</td>
<td>Bilateral temporal L&gt;R</td>
<td>Negative</td>
<td>L frontal</td>
<td>3360/420</td>
<td>381 024</td>
<td>4.43</td>
<td>0.006</td>
</tr>
<tr>
<td>7</td>
<td>R frontal</td>
<td>Negative</td>
<td>L frontal</td>
<td>5904/738</td>
<td>–122 242</td>
<td>4.23</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>R frontal</td>
<td>4512/564</td>
<td>061 840</td>
<td>4.23</td>
<td>0.002</td>
</tr>
</tbody>
</table>

The cluster(s) reaching significance at p<0.05 uncorrected are listed. The contribution of global VT to variance was removed by an ANCOVA by group. Underline indicates concordance between the cluster of increase and the location of the presumed epileptogenic zone, where known. ANCOVA, analysis of covariance; EEG, electroencephalography; ID, identifying number; IFG, inferior frontal gyrus; L/R, left/right; mm, millimeters; MRI, magnetic resonance imaging; VT, volume-of-distribution.
Interestingly, each participant in that temporal lobe epilepsy (TLE) cohort showed temporal hypometabolism on \(^{18}F\) FDG-PET, so the results could have been significantly confounded by cerebral hypoperfusion. Four of our patients had normal \(^{18}F\)FDG-PET, one of whom had a focal increase in \(^{18}F\)GE-179 \(V_T\). The absence of hypometabolism may have facilitated visualisation of activated NMDA receptors in our cohort. Alternatively, our cohort might have had more actively spiking cortex, and thus possibly greater NMDA receptor activation.

A striking and unanticipated finding of our study was reduced \(V_T\) in the small number of patients with focal epilepsies who were taking antidepressants, suggesting that either depression or the use of antidepressant drug constituted an additional confounder. Our finding is in keeping with the mounting evidence for the action of antidepressant drugs at NMDA receptors including tricyclics\(^{52–56}\) and serotonin-selective reuptake inhibitors\(^{56,57–60}\), such as fluoxetine,\(^{57,59–61}\) the two classes used by patients in this study. While our findings may represent the first in vivo evidence of an NMDA-mediated mechanism of action of antidepressants (the extent of which is likely to vary between drugs), caution is warranted as, given the sample size, the result could be due to random chance. Hence, in order to better understand \(^{18}F\)GE-179 binding, a larger study is required, which would compare \(^{18}F\)GE-179 binding between unmedicated patients with depression and those taking antidepressants. It will also be of interest to ascertain whether AEDs that are likely to vary between drugs, caution is warranted as, given the sample size, the result could be due to random chance. Hence, in order to better understand \(^{18}F\)GE-179 binding, a larger study is required, which would compare \(^{18}F\)GE-179 binding between unmedicated patients with depression and those taking antidepressants. It will also be of interest to ascertain whether AEDs that are characterised by use-dependent inhibition of NMDA receptor function (such as felbamate\(^{62–64}\)), or certain combinations of AEDs, affect NMDA receptor binding.

A recent multicentre review concluded that administration of the NMDA receptor antagonist ketamine ‘likely’ or ‘possibly’ contributed to the achievement of control in 32% of (19 of 60) episodes, whereas treatment was discontinued due to adverse events in approximately 8%.\(^{64}\) Smaller series have reported greater success.\(^{65,66}\) Similarly to \(^{18}F\)GE-179,\(^{38}\) ketamine binds to the PCP site in the NMDA ion channel pore.\(^{67}\) Hence, the demonstration of increased NMDA receptor activation via \(^{18}F\)GE-179 PET might aid the stratification of patients with refractory status epilepticus.

Limitations of this proof-of-principle study include the small and heterogeneous population. While \(^{18}F\)GE-179 has a low affinity for other CNS receptors in vitro,\(^{38}\) we cannot exclude the possibility that non-specific binding confounded the analyses. Further studies are needed to confirm our findings, and to quantify reproducibility and specificity of \(^{18}F\)GE-179 binding in vivo.

In conclusion, our results provide in vivo evidence for widespread increases in activated NMDA receptor availability in patients with focal epilepsies. A PET radioligand that reliably demonstrates focal increases in NMDA receptor activity in humans in vivo would hold potential as a method to investigate epileptogenesis in vivo after brain injury, to investigate the role of activated NMDA receptor availability in other conditions, and possibly in the presurgical investigation of patients with refractory focal epilepsy.

Author affiliations
1Division of Neuroscience, Department of Medicine, Imperial College London, London, UK
2Medical Research Council Clinical Sciences Centre, London, UK
3Division of Imaging Sciences & Biomedical Engineering, Faculty of Life Sciences & Medicine, King’s College London, London, UK
4Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
5MRI Unit, Epilepsy Society, Chalfont St. Peter, UK
6The Neurodis Foundation, CERMEP Imagerie du Vivant, Lyon, France
7Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children NHS Trust, London, UK
8GE Healthcare plc, The Grove Centre, Amersham, UK
9National Hospital for Neurology and Neurosurgery, London, UK
10Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark

Acknowledgements The authors thank the staff of Hammersmith Imanet Limited and MDX Discovery for their assistance with \(^{18}F\)GE-179 production and data acquisition, and similarly the radiographers of Epilepsy Society. They thank all the participants.
Epilepsy

Contributors CJM contributed to the design of the study, was primarily responsible for data acquisition and analysis, and prepared the manuscript drafts. MJK contributed to conceptualisation and design of the study, data review and manuscript revision. AH contributed to data analysis and review, and manuscript revision. DARBB contributed to PET data acquisition and manuscript revision. RMP reported the EEG data. SL contributed to conceptualisation and design of the study, and facilitated production of the radioligand at Hammersmith Imanet Ltd. PAI and WT contributed to conceptualisation and design of the study, data review and manuscript revision. They both also facilitated production of the radioligand at Hammersmith Imanet Ltd. CM reported on the MRIs. MRS assisted with MRI acquisition, and co-registration of fMRI and PET data sets. DJB contributed to conceptualisation and design of the study, submissions to regulatory bodies and manuscript revision. JSF contributed to conceptualisation and design of the study, data review and manuscript revision. JSD was primarily responsible for identification of the patients with focal epilepsy.

Funding This study was supported by the Medical Research Council (MRC) Clinical Sciences Centre and GE Healthcare plc. Open access fee and colour figures fees are paid by GE Healthcare plc.

Competing interests CJM, MJK and JSD are grateful for support from the NIHR Biomedical Research Centre funding scheme to the UCLH/UCL BRC. Authors affiliated with the Division of Neuroscience, Department of Medicine, Imperial College London, London, UK, are grateful for support by the NIHR Biomedical Research Centre. SL, PAI, WT and DJB are or were employees of GE Healthcare plc at the time of the study, which they report as a conflict of interest. CJM, JSD and MJK have received fees from GE Healthcare plc. CJM was supported by a MRC Doctoral Training Account (3+1) studentship that was awarded by Imperial College London, London, UK, are grateful for support by the NIHR Biomedical Research Centre. SL, PAJ, WT and DJB are or were employees of GE Healthcare plc.

UCLH/UCL Biomedical Research Centre. JSD has received fees for organising Doctoral Training Account (3+1) studentship that was awarded by Imperial College London, London, UK, are grateful for support by the NIHR Biomedical Research Centre. MJK have received fees from GE Healthcare plc. CJM was supported by a MRC Doctoral Training Account (3+1) studentship that was awarded by Imperial College London, London, UK, are grateful for support by the NIHR Biomedical Research Centre. SL, PAJ, WT and DJB are or were employees of GE Healthcare plc.

Ethics approval Royal Marsden Hospital National Health Service Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The authors have submitted all major results from the study for publication. Unpublished data consist of individual imaging data sets and are only available to the investigators at present. Any request for data can be addressed to the corresponding author; any data sharing will be subject to restrictions based on anonymisation rules.

Open access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


NMDA receptor binding in focal epilepsies


*J Neurol Neurosurg Psychiatry* published online May 19, 2015

Updated information and services can be found at:
http://jnnp.bmj.com/content/early/2015/05/19/jnnp-2014-309897

These include:

**References**
This article cites 67 articles, 16 of which you can access for free at:
http://jnnp.bmj.com/content/early/2015/05/19/jnnp-2014-309897#BIBL

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Open access (239)
- Epilepsy and seizures (846)
- Drugs: musculoskeletal and joint diseases (259)
- Radiology (1747)
- Radiology (diagnostics) (1309)
- Mood disorders (including depression) (221)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/